Takeda navigates Vyvanse patent cliff with cost cuts, pipeline gains

Takeda Pharmaceutical (NYSE:TAK) reported fiscal year 2025 results that met its revised management guidance, as the company utilized aggressive operational savings to buffer the impact of generic competition for its top-selling ADHD medication, Vyvanse.

While revenue saw a slight contraction, the Tokyo-based drugmaker’s bottom line was bolstered by a significant reduction in operating expenses and late-stage clinical milestones that signal a transition toward its next generation of growth drivers.

For the fiscal year ended March 31, 2026, revenue decreased 1.7% at actual exchange rates, primarily due to the loss of exclusivity for Vyvanse.

This decline was partially mitigated by the steady performance of Takeda’s "Growth and Launch" portfolio, which aims to replace aging blockbusters.

On a constant exchange rate basis, core revenue fell 2.6%, highlighting the scale of the patent headwind the company faced throughout the period.

Despite the top-line pressure, Takeda’s profitability metrics remained resilient.

Core operating profit edged up 0.8% at actual exchange rates, supported by a company-wide initiative to lower operating expenses while maintaining R&D investment.

Reported operating profit saw a more dramatic increase of 19.3%, reflecting a step-down in amortization expenses related to Vyvanse and a reduction in restructuring costs compared to the previous year.

The company’s earnings per share reflected this operational efficiency, with reported EPS surging 78.1% year-on-year.

Core EPS, which strips out certain non-recurring items, increased 5.2% at actual exchange rates.

Takeda concluded the year with adjusted free cash flow of 684.5 billion yen, a figure in line with previous forecasts that leaves the firm with a strong cash position to fund upcoming commercial launches.

Looking ahead, Takeda is pivoting toward a refreshed pipeline following several key clinical successes.

The company noted positive Phase 3 readouts for its narcolepsy treatment oveporexton, the blood disorder therapy rusfertide, and zasocitinib.

With regulatory submissions already completed for oveporexton and rusfertide, the company is now shifting its focus toward global launch preparations to offset the continued normalization of the Vyvanse franchise.